Synergy Empire Limited Reports Consultancy Revenue Growth and Strategic Shift Towards Biopharmaceuticals

Synergy Empire Limited reported its financial results for the six months ending September 30, 2024, revealing a consultancy revenue of $15,000, a significant increase from zero revenue in the same period last year. The company incurred a net loss of $28,485, a slight improvement compared to a net loss of $70,317 for the six months ending September 30, 2023. The loss from operations for the three months ending September 30, 2024, was $15,861, compared to a loss of $23,504 in the prior year. The increase in revenue is attributed to the company's shift in focus from asset leasing to consultancy services for restaurant owners, following the divestiture of its subsidiaries in January 2024.

The financial position of Synergy Empire has changed notably, with total assets decreasing from $44,914 as of March 31, 2024, to $5,200 as of September 30, 2024. This decline is primarily due to the disposal of subsidiaries, which has also resulted in a negative working capital of $335,364. The company’s liabilities decreased from $451,793 to $340,564 during the same period, reflecting a reduction in other payables and accrued expenses. The stockholders' deficit improved from $(406,879) to $(335,364), largely due to the issuance of 10 million shares of preferred stock valued at $2,155,000 as part of an acquisition agreement with Meluha Therapeutics Berhad.

Operationally, Synergy Empire has transitioned to a consultancy model, specializing in restaurant and kitchen management. The company reported a customer count of one for the six months ended September 30, 2024, which accounted for 100% of its revenue. The company has also seen a significant increase in general and administrative expenses, which rose to $43,485 from $29,690 in the previous year, primarily due to bad debt write-offs. The company’s employee headcount and engagement metrics were not disclosed in the filing.

Looking ahead, Synergy Empire has executed an Acquisition and Stock Purchase Agreement with Meluha Therapeutics Berhad, which is expected to be finalized by March 28, 2025. This acquisition marks a strategic pivot towards the biopharmaceutical sector, focusing on contract manufacturing and research and development of medical products. The company anticipates that this shift will enhance its operational efficiency and profitability. However, the filing also highlights concerns regarding the company's ability to continue as a going concern, given its accumulated deficit and reliance on future financing to support operations. The management is optimistic about securing additional funding but acknowledges the uncertainty surrounding this endeavor.